Xeris Pharmaceuticals | XERS - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Celltrion KRW 626.11B 81.75B 2025-09
Cspc Pharmaceutical CNY 4.34B 333.68M 2025-09
Deva Holding AS TRY 1.32B 235.77M 2023-09
Dianthus Therapeutics USD 396K 203K 2025-09
Divis Laboratories Ltd INR 16.59B 2.05B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Kangmei Pharma CNY 270.29M 20.26M 2025-09
Knight Therapeutics CAD 44.83M 9.96M 2025-06
Laboratorios Farma EUR 105.28M 177.08M 2025-06
Medical Developments International AUD 7.35M 7.37M 2025-06
Nektar Therapeutics USD 13.75M 650K 2024-06
Neuren Pharmaceuticals AUD 6.69M 6.37M 2025-06
Organigram Holdings CAD 31.84M 23.88M 2025-09
Pacira USD 142.25M 11.34M 2025-12
Perrigo USD 362.2M 14.9M 2025-12
Pharma Mar EUR 86.7M 53.34M 2025-12
Qiagen NV USD 325.27M 19.53M 2025-12
Sartorius EUR 393.2M 23M 2025-09
Sino Biopharmaceutical CNY 10.5B 2.53B 2024-12
Supernus Pharmaceuticals USD 164.04M 15.23M 2025-12
Tilray USD 67.63M 15.62M 2025-03
Zz Pientze Pharmaceu CNY 296.13M 1.1B 2025-06